Neurocrine Biosciences Inc Revenue Growth Rates (NBIX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neurocrine Biosciences Inc   (NASDAQ: NBIX)
 

NBIX's Revenue Growth by Quarter and Year

Neurocrine Biosciences Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NBIX Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 959.00
1st Quarter March 814.50
FY 1,773.50

NBIXs Annual Revenue
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2025 $ 2,860.50 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2024 $ 2,355.30 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2023 $ 1,887.10 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2022 $ 1,488.70 millions
Neurocrine Biosciences Inc 's Revenue in the fiscal year 2021 $ 1,133.50 millions




NBIX Revenue second quarter 2026 Y/Y Growth Comment
Neurocrine Biosciences Inc reported Revenue improvement of 39.49% year on year in the second quarter 2026, to $ 959.00 millions, this is lower than Neurocrine Biosciences Inc 's recent average Revenue surge of 201.27%.

Looking into second quarter 2026 results within Biotechnology & Pharmaceuticals industry 24 other companies have achieved higher Revenue growth. While Neurocrine Biosciences Inc ' s Revenue rise of 39.49% ranks overall at the positon no. 580 in the second quarter 2026.


NBIX Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 28.33 % 21.84 % 25.05 %
3rd Quarter September - 27.78 % 24.72 % 28.59 %
2nd Quarter June 39.49 % 16.49 % 30.37 % 19.7 %
1st Quarter March 42.25 % 11.12 % 22.57 % 35.35 %
FY   - 21.45 % 24.81 % -

Financial Statements
Neurocrine Biosciences Inc 's second quarter 2026 Revenue $ 959.00 millions NBIX's Income Statement
Neurocrine Biosciences Inc 's second quarter 2025 Revenue $ 687.50 millions Quarterly NBIX's Income Statement


NBIX Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - 1.33 % 0.9 % 3.29 %
3rd Quarter September - 15.62 % 5.4 % 10.18 %
2nd Quarter June 17.74 % 20.07 % 14.54 % 7.68 %
1st Quarter March 1.12 % -8.78 % 0.02 % 2.04 %
FY (Year on Year)   - 21.45 % 24.81 % -


Back to NBIX Growth rate Comparisons >> Back to NBIX Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #580

Revenue Y/Y Growth Statistics
High Average Low
7987.14 % 201.27 % -100 %
(Dec 31 2019)   (Dec 31 2013)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #25
Healthcare Sector #138
Overall #580
Revenue Y/Y Growth Statistics
High Average Low
7987.14 % 201.27 % -100 %
(Dec 31 2019)   (Dec 31 2013)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Neurocrine Biosciences Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
859.34 % 38.38 % -100 %
(Sep 30 2017)  


NBIX's II. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the II. Quarter 2026 below company average Revenue jump of 17.74% quarter on quarter, to $ 959.00 millions.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neurocrine Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 552.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #104
Overall #552
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #104
Overall #552
Revenue Q/Q Growth Statistics
High Average Low
859.34 % 38.38 % -100 %
(Sep 30 2017)  


NBIX's II. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the II. Quarter 2026 below company average Revenue jump of 17.74% quarter on quarter, to $ 959.00 millions.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neurocrine Biosciences Inc 's Revenue growth quarter on quarter, overall rank is 552.


Neurocrine Biosciences Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 3,373.90 $ 3,102.40 $ 2,860.50 $ 2,682.70 $ 2,509.90
Y / Y Revenue Growth (TTM) 34.42 % 28.59 % 21.45 % 19.61 % 18.42 %
Year on Year Revenue Growth Overall Ranking # 718 # 620 # 78 # 155 # 403
Seqeuential Revenue Change (TTM) 8.75 % 8.46 % 6.63 % 6.88 % 4.03 %
Seq. Revenue Growth (TTM) Overall Ranking # 2216 # 1983 # 402 # 1461 # 1318


Cumulative Revenue growth Comment
Although Neurocrine Biosciences Inc 's Annual Revenue growth year on year were below company's average 63.48% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.42% year on year, from 28.59% in Mar 31 2026.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 718.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 158
Overall # 718

Revenue TTM Y/Y Growth Statistics
High Average Low
539.85 %
 63.48 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 320
S&P 500 # 2216
Cumulative Revenue growth Comment
Although Neurocrine Biosciences Inc 's Annual Revenue growth year on year were below company's average 63.48% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 34.42% year on year, from 28.59% in Mar 31 2026.

In the Healthcare sector 157 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 620 to 718.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 37
Healthcare Sector # 158
Overall # 718

Revenue TTM Y/Y Growth Statistics
High Average Low
539.85 %
63.48 %
-26.33 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 37
Sector # 320
S&P 500 # 2216




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBIX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Hyperfine Inc 67.70%$ 67.698 millions
Alnylam Pharmaceuticals Inc 66.86%$ 66.856 millions
Emergent Biosolutions Inc 66.29%$ 66.288 millions
Vivos Therapeutics Inc 65.69%$ 65.691 millions
Iovance Biotherapeutics inc 65.65%$ 65.654 millions
Billiontoone Inc 64.40%$ 64.403 millions
Anteris Technologies Global Corp 63.27%$ 63.269 millions
Nexgel Inc 63.24%$ 63.242 millions
Carlsmed Inc 59.58%$ 59.575 millions
Sonoma Pharmaceuticals Inc 59.55%$ 59.552 millions
Arcutis Biotherapeutics Inc 59.33%$ 59.331 millions
Nephros Inc 58.55%$ 58.551 millions
Bioadaptives Inc 54.95%$ 54.955 millions
Zevra Therapeutics Inc 53.25%$ 53.251 millions
Beyond Air Inc 52.94%$ 52.941 millions
Caredx Inc 52.23%$ 52.226 millions
Bioxcel Therapeutics Inc 51.67%$ 51.667 millions
Glaukos Corp50.63%$ 50.628 millions
Heartflow Inc 49.80%$ 49.801 millions
Coya Therapeutics Inc 48.97%$ 48.974 millions
Travere Therapeutics Inc 48.17%$ 48.174 millions
Halozyme Therapeutics Inc 47.67%$ 47.673 millions
Eli Lilly And Company47.67%$ 47.670 millions
Rhythm Pharmaceuticals Inc 46.91%$ 46.911 millions
Axsome Therapeutics Inc 45.54%$ 45.543 millions
Guardant Health Inc 44.33%$ 44.332 millions
Omada Health Inc 43.27%$ 43.273 millions
Mannkind Corporation42.92%$ 42.922 millions
Butterfly Network Inc 42.47%$ 42.466 millions
Beta Bionics Inc 42.26%$ 42.261 millions


About Neurocrine Biosciences Inc Revenue Growth Rates (NBIX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neurocrine Biosciences Inc (CIK 914475).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0000914475-26-000037
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neurocrine Biosciences Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.